MedTrace Logo

Pharmacokinetics of Propofol in Morbidly Obese Patients

NCT01536002 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-05-31

No results posted yet for this study

Summary

The objectives of this study are

* To determine PK of propofol in bariatric patients
* To identify the physiological variables that induce propofol PK changes in bariatric patients, when compared to a normal-weight population.
* To define context-sensitive half-time profiles for propofol in bariatric patients.

Conditions

  • Obesity, Morbid

Interventions

DRUG

Propofol

Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Tom Heier, MD,PhD · Oslo University Hospital, Oslo, Norway

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-07
Primary Completion
2014-05-07
Completion
2014-05-07

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536002 on ClinicalTrials.gov